Charles River Laboratories International (CRL) return on equity (ROE)

Return on equity · fiscal 2025
-4.6%

Charles River Laboratories International (CRL) earned a return on equity of -4.6% in fiscal 2025 (the year ended December 31, 2025). That is 4.9 percentage points lower than the 0.3% of fiscal 2024. Figures as of 17 Nov 2026, 20:46 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-4.6%
Change on fiscal 2024
−4.9 pts
Highest on record
20.9%fiscal 2011
Lowest on record
-49.0%fiscal 2010
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Charles River Laboratories International return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 20.9% in fiscal 2011 and the lowest -49.0% in fiscal 2010. The fiscal 2025 figure is higher than in 12% of the 17 earlier fiscal years on record, whose median is 16.0%.

History · 18 fiscal years

Return on equity by fiscal year

Charles River Laboratories International return on equity (ROE), year by year

Charles River Laboratories International (CRL) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-4.6% 4.9 pts down
20240.3% 12.9 pts down
202313.2% 3.1 pts down
202216.3% 0.9 pts up
202115.4% 1.8 pts down
202017.2% 1.8 pts up
201915.4% 1.8 pts down
201817.2% 5.4 pts up
201711.8% 6.7 pts down
201618.5% 1.9 pts down
201520.4% 1.5 pts up
201418.8% 2.8 pts up
201316.0% 0.2 pts down
201216.3% 4.6 pts down
201120.9% 69.9 pts up
2010-49.0% 57.3 pts down
20098.3% 50.6 pts up
2008-42.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Charles River Laboratories International and comparable companies
CompanyReturn on equityFiscal year
Medpace Holdings MEDP98.3%2025
Revvity RVTY3.3%2025
Exelixis EXEL36.2%2025
Charles River Laboratories International CRL-4.6%2025
Neurocrine Biosciences NBIX14.7%2025
Ascendis Pharma ASND-221.5%2022

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRL

Charles River Laboratories International, figure by figure

Charles River Laboratories International (CRL) overview: price, valuation and scorecardAll health care companies by market value

Charles River Laboratories International return on equity (ROE): questions and answers

What is Charles River Laboratories International's return on equity?

Charles River Laboratories International (CRL) earned a return on equity of -4.6% in fiscal 2025 (the year ended December 31, 2025). That is 4.9 percentage points lower than the 0.3% of fiscal 2024.

Is Charles River Laboratories International's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 12% of the 17 earlier fiscal years on record, whose median is 16.0%.

What are the highest and lowest return on equity figures on record for Charles River Laboratories International?

Across the 18 fiscal years on record (2008–2025), the highest was 20.9% in fiscal 2011 and the lowest -49.0% in fiscal 2010.

How is Charles River Laboratories International's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Charles River Laboratories International (CRL) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/CRL/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.